Mount Sinai DoctorsTreats Children
Accepting New Patients
Stanislav Lazarev, MD
Radiation Oncology
About Me
Dr. Stanislav (Stas) Lazarev, MD, is an Associate Professor in the Department of Radiation Oncology. He provides patient care at both Mount Sinai Hospital and the New York Proton Center. Dr. Lazarev specializes in the personalized treatment of central nervous system (CNS) tumors, including primary and metastatic brain and spinal cord tumors in both children and adults, leptomeningeal disease (LMD), pediatric tumors, and the re-irradiation of CNS, thoracic, and hepatobiliary tumors. His other major focus is the radiation treatment of primary thoracic and hepatobiliary tumors using proton beam therapy. His clinical expertise includes proton craniospinal irradiation (CSI) for LMD, proton re-irradiation, proton radiotherapy for pediatric tumors, and low-dose re-irradiation for recurrent pediatric diffuse intrinsic pontine gliomas (DIPGs) and diffuse midline gliomas (DMGs) H3 K27-altered WHO Grade 4.
In recognition of his dedication to compassionate and effective communication, Dr. Lazarev was honored with the Cullman Family Award for Excellence in Provider Communication in 2024. Out of over 117,000+ providers surveyed nationwide, Dr. Lazarev was among 89 Mount Sinai providers who ranked in the top 5% nationally in provider communication, as measured by the Press Ganey 2023 patient experience surveys.
Dr. Lazarev’s dedication to education has been recognized with the Association of Residents in Radiation Oncology (ARRO) Educator of the Year Award in both 2022 and 2024. In 2023, he was honored with the STAR Employee Award for his exceptional service and commitment to Mount Sinai’s core values. From 2022 to 2024, Dr. Lazarev served as the Associate Program Director of Mount Sinai Radiation Oncology Residency Program.
Dr. Lazarev’s research focuses on proton craniospinal irradiation in LMD, re-irradiation for recurrent primary brain tumors, and proton therapy for pediatric cancers. He serves as the institutional principal investigator for the NRG Oncology BN012 clinical trial, a randomized phase III study comparing pre-operative versus post-operative stereotactic radiosurgery for resectable brain metastases. His work has been widely published in leading journals, including Nature Reviews Clinical Oncology, Neuro-Oncology, International Journal of Radiation Oncology, Biology, Physics, Advances in Radiation Oncology, and The Oncologist.
Internationally, Dr. Lazarev is actively involved in the Brain Tumors in Latin America Program, an initiative of St. Jude Children’s Research Hospital. He participates in a weekly Global Pediatric CNS Tumor Board, collaborating with leading pediatric oncologists from the USA, Canada, Germany, and Spain to provide expertise on complex pediatric CNS cases from low- and middle-income countries in Central and South America. Dr. Lazarev also contributes to the National Ewing Sarcoma Tumor Board, providing radiation oncology expertise for challenging casesinvolving both pediatric and adult patients with Ewing sarcoma. His clinical insights are regularly sought by colleagues worldwide.
Dr. Lazarev is fluent in Russian, Spanish, and Portuguese, proficient in French, has basic knowledge of Hebrew, and is currently learning Arabic to better communicate with his diverse patient population. He believes that speaking to patients in their native language fosters trust and improves the quality of care.
Beyond his clinical and academic responsibilities, Dr. Lazarev actively contributes to the field of radiation oncology through his involvement with TheMedNet.org and engagement with the professional community on X.com (formerly Twitter). His perspectives on neuro-oncology, CNS radiation oncology, and pediatric radiation oncology have garnered attention and fostered meaningful discussions among colleagues. Dr. Lazarev is also a sought-after speaker at national and international academic forums, where he shares insights and advances to further the field.
Dr. Lazarev’s work reflects his dedication to advancing cancer care across all settings, from local clinical practice to national and international initiatives, ensuring that his expertise benefits diverse patient populations while driving innovations in radiation oncology.
Language
Position
Hospital Affiliations
- Mount Sinai Queens
- The Mount Sinai Hospital
About Me
Dr. Stanislav (Stas) Lazarev, MD, is an Associate Professor in the Department of Radiation Oncology. He provides patient care at both Mount Sinai Hospital and the New York Proton Center. Dr. Lazarev specializes in the personalized treatment of central nervous system (CNS) tumors, including primary and metastatic brain and spinal cord tumors in both children and adults, leptomeningeal disease (LMD), pediatric tumors, and the re-irradiation of CNS, thoracic, and hepatobiliary tumors. His other major focus is the radiation treatment of primary thoracic and hepatobiliary tumors using proton beam therapy. His clinical expertise includes proton craniospinal irradiation (CSI) for LMD, proton re-irradiation, proton radiotherapy for pediatric tumors, and low-dose re-irradiation for recurrent pediatric diffuse intrinsic pontine gliomas (DIPGs) and diffuse midline gliomas (DMGs) H3 K27-altered WHO Grade 4.
In recognition of his dedication to compassionate and effective communication, Dr. Lazarev was honored with the Cullman Family Award for Excellence in Provider Communication in 2024. Out of over 117,000+ providers surveyed nationwide, Dr. Lazarev was among 89 Mount Sinai providers who ranked in the top 5% nationally in provider communication, as measured by the Press Ganey 2023 patient experience surveys.
Dr. Lazarev’s dedication to education has been recognized with the Association of Residents in Radiation Oncology (ARRO) Educator of the Year Award in both 2022 and 2024. In 2023, he was honored with the STAR Employee Award for his exceptional service and commitment to Mount Sinai’s core values. From 2022 to 2024, Dr. Lazarev served as the Associate Program Director of Mount Sinai Radiation Oncology Residency Program.
Dr. Lazarev’s research focuses on proton craniospinal irradiation in LMD, re-irradiation for recurrent primary brain tumors, and proton therapy for pediatric cancers. He serves as the institutional principal investigator for the NRG Oncology BN012 clinical trial, a randomized phase III study comparing pre-operative versus post-operative stereotactic radiosurgery for resectable brain metastases. His work has been widely published in leading journals, including Nature Reviews Clinical Oncology, Neuro-Oncology, International Journal of Radiation Oncology, Biology, Physics, Advances in Radiation Oncology, and The Oncologist.
Internationally, Dr. Lazarev is actively involved in the Brain Tumors in Latin America Program, an initiative of St. Jude Children’s Research Hospital. He participates in a weekly Global Pediatric CNS Tumor Board, collaborating with leading pediatric oncologists from the USA, Canada, Germany, and Spain to provide expertise on complex pediatric CNS cases from low- and middle-income countries in Central and South America. Dr. Lazarev also contributes to the National Ewing Sarcoma Tumor Board, providing radiation oncology expertise for challenging casesinvolving both pediatric and adult patients with Ewing sarcoma. His clinical insights are regularly sought by colleagues worldwide.
Dr. Lazarev is fluent in Russian, Spanish, and Portuguese, proficient in French, has basic knowledge of Hebrew, and is currently learning Arabic to better communicate with his diverse patient population. He believes that speaking to patients in their native language fosters trust and improves the quality of care.
Beyond his clinical and academic responsibilities, Dr. Lazarev actively contributes to the field of radiation oncology through his involvement with TheMedNet.org and engagement with the professional community on X.com (formerly Twitter). His perspectives on neuro-oncology, CNS radiation oncology, and pediatric radiation oncology have garnered attention and fostered meaningful discussions among colleagues. Dr. Lazarev is also a sought-after speaker at national and international academic forums, where he shares insights and advances to further the field.
Dr. Lazarev’s work reflects his dedication to advancing cancer care across all settings, from local clinical practice to national and international initiatives, ensuring that his expertise benefits diverse patient populations while driving innovations in radiation oncology.
Language
Position
Hospital Affiliations
- Mount Sinai Queens
- The Mount Sinai Hospital
